The past, present and future of breast cancer research in China

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 1-5

  Hong, Wei ^a   Dong, Erdan ^a  

^a NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA   (China)

Author keywords

Breast cancer; China; Funding; Research

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; BREAST SELF EXAMINATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CHINA; CLINICAL RESEARCH; DISEASE ASSOCIATION; GENE FUNCTION; GENE IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SURVIVAL RATE; TRANSLATIONAL RESEARCH;

BREAST CANCER; CHINA; FUNDING; RESEARCH;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHINA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PUBLICATIONS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84903739097     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.007     Document Type: Review

References (31)

1. H.T. Kimm, Y. Liu, Carcinosarcoma of the breast: a study of eight cases, Chin. Med. J. (Shanghai) 62(38) (1943).
2. Yu F., Yao H., Zhu P.C., Zhang X.Q., Pan Q.H., Gong C., Huang Y.J., Hu X.Q., Su F.X., Lieberman J., Song E. Iet-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131(6):1109-1123.
3. Lu D., Wu Y., Wang Y., Ren F., Wang D., Su F., Zhang Y., Yang X., Jin G., Hao X., He D., Zhai Y., Irwin D.M., Hu J., Sung J.J., Yu J., Jia B., Chang Z. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell 2012, 21(1):92-104.
4. Shi L., Sun L.Y., Li Q., Liang J., Yu W.H., Yi X., Yang X.H., Li Y.Y., Han X., Zhang Y., Xuan C.H., Yao Z., Shang Y.F. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. USA 2011, 108(18):7541-7546.
5. Wang Y., Zhang H., Chen Y., Sun Y., Yang F., Yu W., Liang J., Sun L., Yang X., Shi L., Li R., Li Y., Zhang Y., Li Q., Yi X., Shang Y. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009, 138(4):660-672.
6. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., Liu B., Deng H., Wang F., Lin L., Yao H., Su F., Anderson K.S., Liu Q., Ewen M.E., Yao X., Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19(4):541-555.
7. Zeng Q.Q., Li W.D., Lu D., Wu Z.Z., Duan H.X., Luo Y.T., Feng J., Yang D.L., Fu L., Yan X.Y. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109(4):1127-1132.
8. Pan X., Zhou T., Tai Y.H., Wang C., Zhao J., Cao Y., Chen Y., Zhang P.J., Yu M., Zhen C., Mu R., Bai Z.F., Li H.Y., Li A.L., Liang B., Jian Z., Zhang W.N., Man J.H., Gao Y.F., Gong W.L., Wei L.X., Zhang X.M. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat. Med. 2011, 17(6):708-714.
9. Shi L., Dong B., Li Z., Lu Y., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., Wang Z., Xie Y. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 2009, 27(21):3423-3429.
10. Wu H., Chen Y., Liang J., Shi B., Wu G., Zhang Y., Wang D., Li R., Yi X., Zhang H., Sun L., Shang Y. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005, 438(7070):981-987.
11. Stern H.M. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci. Transl. Med. 2012, 4(127). 127rv122-127rv122.
12. Park S., Jiang Z.J., Mortenson E.D., Deng L.F., Radkevich-Brown O., Yang X.M., Sattar H., Wang Y., Brown N.K., Greene M., Liu Y., Tang J., Wang S.D., Fu Y.X. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18(2):160-170.
13. Wang S., Chen C., Meng Y., Hu S., Zheng L., Song J., Zhang D., Li B., Guo Y. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody. Cancer Lett. 2012, 325(2):214-219.
14. http://clinicaltrial.gov/ct2/show/NCT01439191.
15. http://www.clinicaltrials.gov/ct2/show/NCT01291667.
16. Fang Y., Chen Y., Yu L., Zheng C., Qi Y., Li Z., Yang Z., Zhang Y., Shi T., Luo J., Liu M. Inhibition of breast cancer metastases by a novel inhibitor of TGFbeta receptor 1. J. Natl. Cancer Inst. 2013, 105(1):47-58.
17. http://clinicaltrial.gov/ct2/show/NCT01116869.
18. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., Ruan J.B., Mao C.Q., Yu F.Y., Zeng M.S., Zang J.Y., Liu Q., Su F.X., Zhang P., Lieberman J., Wang J., Song E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 2012, 4(130). 130ra148.
19. Fan Y., Xu B.H., Yuan P., Ma F., Wang J.Y., Ding X.Y., Zhang P., Li Q., Cai R.G. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann. Oncol. 2013, 24(5):1219-1225.
20. X.H.Z. Wang, B. Wang, L. Wang, J. Zhang, H. Wang, G. Liu, Z. Hu, J. Wu, Z. Shao, P5-19-06: highly effective of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: final report of a phase II trial, in: San Antonio Breast Cancer Symposium, American Association for Cancer Research, San Antonio, TX, 2011, pp. P5-19-06.
21. Guan Z., Xu B., Desilvio M.L., Shen Z., Arpornwirat W., Tong Z., Lorvidhaya V., Jiang Z., Yang J., Makhson A., Leung W.L., Russo M.W., Newstat B., Wang L., Chen G., Oliva C., Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2013.
22. Thomas D.B., Gao D.L., Ray R.M., Wang W.W., Allison C.J., Chen F.L., Porter P., Hu Y.W., Zhao G.L., Pan L.D., Li W., Wu C., Coriaty Z., Evans I., Lin M.G., Stalsberg H., Self S.G. Randomized trial of breast self-examination in Shanghai: final results. J. Natl. Cancer Inst. 2002, 94(19):1445-1457.
23. Shu X.O., Zheng Y., Cai H., Gu K., Chen Z., Zheng W., Lu W. Soy food intake and breast cancer survival. JAMA - J. Am. Med. Assoc. 2009, 302(22):2437-2443.
24. Chen X.L., Lu W., Zheng Y., Gu K., Chen Z., Zheng W., Shu X.O. Exercise, tea consumption, and depression among breast cancer survivors. J. Clin. Oncol. 2010, 28(6):991-998.
25. Dai Q., Gao Y.T., Shu X.O., Yang G., Milne G., Cai Q.Y., Wen W.Q., Rothman N., Cai H., Li H.L., Xiang Y.B., Chow W.H., Zheng W. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai women's health study. J. Clin. Oncol. 2009, 27(15):2482-2488.
26. Cui Y., Shu X.O., Gao Y.T., Wen W.Q., Ruan Z.X., Jin F., Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer (vol 85, pg 263, 2004). Breast Cancer Res. Tr. 2004, 86(1):89.
27. Chen J., Lv Q., Yu M., Zhang X., Gou J. Randomized clinical trial of Chinese herbal medications to reduce wound complications after mastectomy for breast carcinoma. Brit. J. Surg. 2010, 97(12):1798-1804.
28. Mok T.S., Yeo W., Johnson P.J., Hui P., Ho W.M., Lam K.C., Xu M., Chak K., Chan A., Wong H., Mo F., Zee B. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann. Oncol. 2007, 18(4):768-774.
29. http://www.pharmafocusasia.com/clinical_trials/clinical_trial_strategies_china.htm.
30. http://www.bcrc.dk.
31. http://ww5.komen.org/News.aspx.